TheraRadar
← Back
Data updated: Jun 28, 2026

CHENGDU

Generics
OncologyOphthalmologyInfectious Disease Execution: Good

CHENGDU is a generic drug manufacturer focused on Oncology, Ophthalmology, Infectious Disease.

2024
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

CHENGDU at a Glance

  • Fast trial execution (30 months median completion)

CHENGDU's Key Drugs

CHENGDU's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CHENGDU's Recent FDA Approvals

New NDA/BLA approvals for CHENGDU over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CHENGDU's Therapeutic Areas

CHENGDU's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Ophthalmology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 49%
0 drugs Phase 3: 3 Phase 2: 2 Phase 1: 17
Ophthalmology 41%
0 drugs Phase 3: 5 Phase 2: 1 Phase 1: 6
Infectious Disease 6%
0 drugs Phase 2: 2
Dermatology 3%
0 drugs Phase 2: 1
Immunology 1%
0 drugs Phase 1: 1

CHENGDU Pipeline Snapshot

CHENGDU has 38 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 6 Phase 2 and 24 Phase 1.

8
Phase 3
6
Phase 2
24
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 3/5 completed
  • • Speed: 30 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges